{"id":"W2806730227","doi":"10.1200/jco.2018.36.15_suppl.tps1107","title":"BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of <i>PIK3CA</i> mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2<i>–</i>) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fulvestrant; Letrozole; Medicine; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Internal medicine; Mutant; Hormone receptor; Pharmacology; Receptor; Oncology; Endocrinology; Cancer; Estrogen receptor; Biology; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002681501,0.002343385,0.002404386,0.0007790193,0.0005935073,0.001841761,0.002170275,0.00211498,0.007703465],"category_scores_gemma":[0.00114635,0.0008532697,0.002025865,0.0006499552,0.001702831,0.002067513,0.0007471791,0.004443905,0.002045895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001059125,"about_ca_system_score_gemma":0.002427036,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001260207,"about_ca_topic_score_gemma":0.002942667,"domain_scores_codex":[0.9990231,0.000512988,0.00002690265,0.0001492881,0.0001159048,0.0001719035],"domain_scores_gemma":[0.9989408,0.0001595532,0.000177298,0.0001078005,0.00008711468,0.0005274315],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7046402,0.1104449,0.005946935,0.002238774,0.002129156,0.0002630822,0.0006073586,0.001872054,0.05588765,0.001207795,0.01239023,0.1023718],"study_design_scores_gemma":[0.6421708,0.336254,0.005942732,0.00009244181,0.0006030226,0.0005343255,0.0001320891,0.0008343803,0.003893018,0.0004687443,0.009022921,0.00005142704],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762281,0.005466422,0.001216215,0.00111231,0.0003184957,0.005443324,0.004036237,0.0003133994,0.005865409],"genre_scores_gemma":[0.945725,0.007279236,0.006075551,0.003101212,0.0004531874,0.009822632,0.01642391,0.0002353418,0.010884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007703465,"threshold_uncertainty_score":0.0257706,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06887970135663998,"score_gpt":0.4446081298824254,"score_spread":0.3757284285257854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}